Please login to the form below

Not currently logged in
Email:
Password:

daratumumab

This page shows the latest daratumumab news and features for those working in and with pharma, biotech and healthcare.

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

and an anti-CD38 monoclonal antibody, such as Janssen’s Darzalex (daratumumab).

Latest news

More from news
Approximately 8 fully matching, plus 55 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and

  • ASCO 2015: What you missed in Chicago

    In particular, daratumumab in double refractory multiple myeloma represents a truly transformational treatment in this area for patients who have tried all current options[4]. ... In an area dominated by combination trials, daratumumab showed significant

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....